Rick Simpson Oil (RSO) in Logan County, Arkansas: The Complete Guide by OilWell Cannabis
If you’re reading this from your front porch in Paris, scanning it on your phone between shifts at a job in Booneville, or researching quietly in your home near Magazine Mountain because something in your body hurts and nothing else has helped — we see you. Logan County, Arkansas is a place where people still believe in looking someone in the eye, where community matters more than credentials, and where “I’ll figure it out myself” is practically in the water. That’s why this guide exists. That’s why we’re here.
We don’t sell snake oil. We don’t sell hope. We sell a product we built because we had to — because conventional medicine failed someone we loved, because pills made things worse, because when you’re facing down a diagnosis or chronic pain or the kind of insomnia that makes you forget what rested feels like, you deserve to know exactly what you’re putting in your body and exactly why it might help.
OilWell Cannabis was born in Houston, Texas, but the story that built us started in McAllen, right on the border, in a place a lot like Logan County in one crucial way: the system wasn’t built to help people like us. We learned to hustle, to survive, and eventually to build something better. This guide is our open book. Every number, every study, every doubt and limitation — it’s all here. For you in Logan County, for your neighbor in Magazine, for the veteran in Subiaco wrestling with PTSD, for the cancer patient in Scranton driving three hours to Little Rock for treatment and wondering if there’s anything else.
ABOUT RICK SIMPSON AND TRADITIONAL RICK SIMPSON OIL
Who is Rick Simpson (and Why His Story Matters in Logan County)
Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada — a place about as far from Logan County as you can get, but his story hits home here because it’s the same story we’ve all heard whispered at the feed store or shared in a Facebook group for chronic pain survivors. Simpson wasn’t a doctor. He wasn’t a researcher. He was a power engineer, a blue-collar tradesman who got hurt at work in 1997, fell from scaffolding in Moncton, and spent years fighting tinnitus, dizziness, and post-concussion symptoms that doctors couldn’t fix. The medications they gave him either did nothing or made him feel worse. Sound familiar?
When he asked his physician about cannabis, the doctor refused. Simpson started using it anyway — illegally, at a time when even talking about cannabis as medicine could get you labeled a conspiracy theorist. Then in 2003, he noticed three bumps on his arm. His doctor diagnosed basal cell carcinoma. Instead of surgery or radiation, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared in four days. No biopsy confirmation. No independent medical verification. No peer-reviewed study. Just his word, his experience, and the desperate hope of people who had been failed by the system.
That’s the part that resonates in Logan County. We know what it’s like to be told there’s no more that can be done. We know the frustration of driving to Fort Smith or Little Rock for a specialist who shrugs and prescribes another pill that makes you groggy. Simpson’s story became the catalyst for a global movement not because it was scientifically proven, but because it reflected a universal truth: when medicine fails, people will find their own path.
Important context: Simpson’s account is personal testimony, not medical evidence. The absence of clinical documentation means these events cannot be evaluated as scientific proof. They are, however, historically significant as the origin story of Rick Simpson Oil and the reason millions of people worldwide — including many in Logan County — first heard the term “RSO.”
The Crusade: How RSO Went from One Man to a Global Movement
After his 2003 experience, Simpson committed himself to making and giving away cannabis oil for free from his property in Maccan, Nova Scotia. He charged nothing. He claimed to help people with cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and more. In Logan County, where we’ve got neighbors dealing with every one of those conditions, that free-access model touched a nerve. Simpson’s oil wasn’t just a product — it was a defiant act of compassion in a world that criminalized the plant.
His story exploded in 2005 through the documentary Run From The Cure, which became the most shared cannabis advocacy film of its era. For many Logan County residents who first encountered RSO through online forums or private Facebook groups, that documentary was their introduction. It framed cannabis oil as a grassroots challenge to pharmaceutical interests, resonating deeply in communities where folks already distrusted big institutions.
But Simpson’s advocacy brought him into direct conflict with Canadian law. The RCMP raided his property in 2005 and 2009. He was charged with cultivation, possession, and trafficking. Eventually he left Canada for Europe, continuing his work from Croatia and the Netherlands. In 2012, he published Phoenix Tears: The Rick Simpson Story and maintained phoenixtears.ca as his platform .
Throughout his public career, Simpson remained uncompromising: he claimed RSO could cure cancer and that pharmaceutical companies and government agencies were actively suppressing this knowledge. He framed his work as a fight against institutional corruption.
Important context: Simpson’s conspiratorial worldview is noted here without endorsement. It reflects a perspective shared by many in the early cannabis movement and is relevant to understanding RSO’s cultural significance. Our position at OilWell is different: we honor Simpson’s contribution to accessibility while committing to evidence-based evaluation of every claim.
The Traditional RSO Protocol: Simpson’s 60-Gram, 90-Day Regimen
Simpson’s core recommendation was a structured oral protocol designed to deliver 60 grams of concentrated cannabis oil over approximately 90 days. He described this as a cancer treatment protocol, though he recommended it for numerous conditions. Here’s exactly what he prescribed :
Goal
Consume 60 grams of concentrated, high-THC cannabis oil over roughly 90 days. Simpson considered this the minimum necessary for a serious cancer treatment course.
Titration Schedule
- Week 1: Begin with a dose the size of half a grain of dry rice — about 10-15 milligrams of oil — taken three times daily (morning, afternoon, before bed). Total daily intake: 30-45 milligrams.
- Weeks 2-5: Double the dose every four days to build THC tolerance gradually. By week 5, reach approximately 1 gram (1,000 milligrams) of oil per day, divided into three doses of roughly 333 milligrams each.
- Weeks 5-12: Maintain the full dose of 1 gram per day until all 60 grams are consumed.
Administration Methods
- Primary method — oral: Place the dose directly under the tongue or swallow. Simpson considered this the most important route for systemic absorption.
- Secondary method — topical: For skin cancers, apply oil directly to lesions, cover with a bandage, change every 3-4 days. Combine with oral dosing for skin cancers.
- Not recommended as primary — inhalation: Simpson acknowledged smoking or vaporizing for immediate symptom relief (pain, nausea) but maintained oral dosing was essential for sustained therapeutic exposure.
Tolerance and Psychoactive Effects
Simpson claimed patients develop significant tolerance to THC’s psychoactive effects within 3-4 weeks. He considered euphoria, sedation, and disorientation minor, temporary side effects and urged patients not to let the “high” discourage them from continuing. He recommended initial nighttime dosing to sleep through the most intense effects and warned against driving or operating machinery during titration.
Post-Protocol Maintenance
After completing the 60-gram course, Simpson recommended maintenance dosing of 1-2 grams of oil per month indefinitely for long-term health and cancer prevention.
Dietary and Lifestyle Recommendations
Simpson advocated reducing sugar intake, avoiding processed foods, and improving overall nutrition, though his dietary advice was secondary and general compared to his detailed oil protocol.
Important Context for Evaluating This Protocol
This protocol was designed by one person based on personal experience, not clinical trials. Several critical points apply:
- No controlled trial validation. No published randomized controlled trials, cohort studies, or well-documented case series evaluate this specific 60-gram/90-day protocol for any condition.
- Assumes crude, unstandardized material. The 60-gram quantity assumes a single-strain, THC-dominant extract with no standardized potency. Traditional RSO THC content varied widely.
- Very high THC exposure. At peak dosing, patients consumed roughly 1 gram of high-THC oil daily. Assuming 60-90% THC content, that’s 600-900 milligrams of delta-9 THC per day — far exceeding anything studied clinically. For context, the FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5-20 milligrams per day.
- Real risks at these doses. Consuming 600-900 milligrams of THC daily carries serious risks: severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder [1][13][14][15].
- Oncology context. Patients with active cancer are medically complex. Using unregulated, unstandardized cannabis oil as primary treatment — potentially in place of proven therapies — introduces harm beyond the oil itself.
In Logan County, where cancer patients already drive hours to Little Rock or Fort Smith for treatment, the idea of delaying proven care for an unverified protocol is especially dangerous. We present this information so you know exactly what you’re evaluating, not to encourage its use without medical guidance.
What Traditional Rick Simpson Oil Actually Was
Traditional RSO wasn’t a standardized product — it was a method. Understanding what Simpson actually made helps Logan County residents evaluate what’s being sold locally as “RSO.”
Source Material
Simpson used high-THC, indica-dominant cannabis strains. He favored heavy, sedating genetics and generally recommended against sativa. There was no strain standardization — the starting material varied by availability and growing season. In Logan County, where cannabis cultivation knowledge is limited and sourcing is restricted, that variability would be a major problem.
Extraction Solvent
Simpson originally used naphtha (a petroleum-based lighter fluid) or 99% isopropyl alcohol. Neither is food-grade. Naphtha may contain benzene, toluene, and other toxic or carcinogenic compounds. Isopropyl alcohol is also not intended for internal consumption. Incomplete solvent purging — nearly impossible to verify without lab equipment — leaves potentially harmful residues in the finished oil.
Extraction Process
- Dry cannabis placed in a bucket
- Cover with solvent, agitate several minutes
- Pour solvent through filter into collection vessel
- Repeat with fresh solvent on same plant material
- Combine washes in rice cooker
- Evaporate solvent at relatively low heat (still high enough to decarboxylate THCa and destroy terpenes)
- Transfer thick, dark oil to syringes
Appearance and Physical Characteristics
Traditional RSO was nearly black, thick, tar-like, sticky, with strong cannabis odor and possible solvent-residual smell. Difficult to handle at room temperature but more fluid when warmed.
Cannabinoid Profile
- Primarily decarboxylated delta-9 THC: Heat converted essentially all THCa to delta-9 THC. Traditional RSO was activated, THC-dominant.
- Naturally occurring minor cannabinoids: Whatever CBD, CBN, CBC, CBG the source strain contained were present at natural ratios, but not controlled, measured, or targeted.
- No ratio control: Profile was entirely determined by genetics and growing conditions.
- Estimated THC content: Likely 60-90% total THC by weight, though never lab-verified in traditional production.
Terpene Content
Minimal to none. Solvent plus high-heat evaporation stripped terpenes. Most cannabis terpenes volatilize at 21-157°C, well below cannabinoid degradation temperatures. Traditional RSO was effectively a cannabinoid-only product.
Standardization and Testing
None. Every batch differed because it depended on starting material, growing conditions, solvent purity, extraction technique, evaporation temperature/duration, and the maker’s process. No Certificate of Analysis, no cannabinoid quantification, no contaminant screening.
Residual Solvent Risk
This is one of the most significant safety concerns. Naphtha and isopropyl alcohol are not food-grade. Incomplete purging leaves residues that are difficult to verify without lab testing. Modern extraction uses food-grade ethanol or supercritical CO₂ specifically to address this problem.
Simpson’s Claims vs. The Evidence Record
Simpson claimed RSO could cure cancer and many other diseases. Let’s evaluate those claims against actual evidence.
What Simpson Was Not
He was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research. He never designed, conducted, funded, or published a clinical trial. He never submitted results to peer review. His evidence base consisted entirely of personal experience, self-reported patient outcomes, and testimonials gathered informally — with no controls, no independent verification, no imaging confirmation, no long-term follow-up, no blinding.
What The Preclinical Literature Shows
- In vitro studies demonstrate THC and CBD can induce apoptosis, inhibit proliferation, and reduce angiogenesis in certain cancer cell lines .
- Animal model studies show some tumor-growth inhibition in mice and rats treated with cannabinoids .
- These findings generated legitimate scientific interest and ongoing research.
What The Preclinical Literature Does NOT Show
- These findings have not translated into proven human cancer cures. The gap between in vitro/animal results and human clinical outcomes is vast.
- No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer.
Institutional Positions
- U.S. National Cancer Institute (NCI): Acknowledges cannabinoids have been studied for potential anticancer effects in laboratory and animal models but does not endorse cannabis or cannabis oil as cancer treatment .
- FDA: Has not approved any cannabis plant product for cancer treatment. Only FDA-approved cannabinoid-related products are for specific indications: Epidiolex (CBD) for certain seizure disorders and dronabinol/nabilone (synthetic THC analogues) for chemotherapy-related nausea and AIDS-related wasting [1].
- Health Canada: Has never approved RSO or cannabis oil as cancer cure.
- NCCIH: States strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea/vomiting, and appetite-related indications in HIV/AIDS — not cancer cure [1].
What Simpson Got Right
He drew attention to cannabinoids as serious biomedical research when the world was ignoring it. His advocacy helped create political, cultural, and social conditions for legal cannabis and cannabinoid research infrastructure. He brought concentrated cannabis oil to widespread public awareness. The term “RSO” remains the most recognized name for full-spectrum cannabis extract.
What He Overstated
The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it’s not supported now. Encouraging patients — particularly cancer patients — to rely on RSO as primary treatment in place of proven oncologic therapies carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in alternative-medicine literature.
In Logan County, where cancer patients already face travel burdens and limited local oncology resources, delaying proven treatment based on unverified claims can be catastrophic. RSO education should complement medical care, not replace it.
The Legacy of Rick Simpson and The Evolution of Modern RSO
The term RSO is now used loosely across the legal cannabis industry. Many products labeled “RSO” bear little resemblance to Simpson’s original. In dispensaries today, RSO can refer to almost any full-spectrum cannabis extract in syringe format, regardless of extraction method, cannabinoid profile, terpene content, or intended use. The term has become generic .
Simpson has been critical of commercial products using the RSO name while departing from his method and philosophy. He believed in DIY, free-access model where anyone could grow cannabis, extract oil, and treat themselves without corporate or governmental intermediaries. He gave oil away for free and urged people to make their own rather than buy from companies .
This philosophical tension is real. Simpson’s model was anti-commercial. The modern industry commercialized, standardized, and regulated what he distributed for free. Whether that’s an improvement (quality control, lab testing, dosing precision) or a betrayal (profit extraction, regulatory gatekeeping) depends on perspective. The cannabis community remains divided.
What is not disputed: modern RSO has evolved substantially, and those changes are directly relevant to the formulas in this document.
Traditional RSO vs. Modern Formulated RSO
| Dimension | Traditional RSO | OilWell Formulated RSO |
|---|---|---|
| Source material | Single high-THC indica strain | Multi-cannabinoid blend from multiple sources |
| Extraction method | Naphtha or isopropyl alcohol | Modern food-grade ethanol or CO₂ methods |
| Cannabinoid profile | THC-dominant, uncontrolled | Seven defined cannabinoids at specific ratios |
| Terpene content | Destroyed by high-heat process | Live terpenes at 5% with defined seven-terpene profile |
| Standardization | None — every batch different | Lab-tested with specific mg/mL targets |
| Lab testing | Not available or performed | Full panel testing for potency, terpenes, pesticides, heavy metals, residual solvents, microbial |
| Residual solvents | Significant risk with naphtha | Controlled and tested |
| Dosing precision | Approximate, syringe-based | Measured per mL with known cannabinoid content (553 mg/mL) |
| Product formats | Single thick oil only | Sublingual oil and vape cartridge with format-specific formulas |
| THCa preservation | No — fully decarboxylated by heat | Yes — THCa included as separate ingredient at 1,500 mg |
| Evidence approach | Anecdotal, personal testimony | Research-backed, evidence-weighted |
Why OilWell’s Formulas Diverge From Traditional RSO
Our formulations are informed by RSO tradition but depart deliberately:
Multi-cannabinoid approach. Traditional RSO relied on whatever single strain the maker grew. Our formulas intentionally include seven cannabinoids because entourage-effect literature suggests potential benefit from cannabinoid diversity [20][29].
Terpene preservation and addition. Traditional RSO had essentially no terpene content. We include live terpenes at 5% with a specific seven-terpene profile because terpene bioactivity is plausible and supported at preclinical level, even if human clinical confirmation remains developing [20][21][23][24][25][26][27][28][29].
THCa as separate ingredient. Traditional RSO fully decarboxylated everything. Our sublingual formula includes THCa at 1,500 mg because the THCa literature suggests potentially relevant non-psychoactive bioactivity that is lost when THCa converts to THC [12].
Reduced delta-9 THC dominance. Traditional RSO was 60-90% delta-9 THC. Our formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg and distributing remaining cannabinoids across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), and CBC (750 mg). This reflects broader cannabinoid research landscape rather than single-compound dominance.
Product format innovation. Simpson envisioned only one format: oral oil from syringe. We offer both 30 mL sublingual oil and 1-gram vape cartridge, each with format-specific formulation acknowledging different pharmacokinetic profiles [14].
Solvent Safety and Extraction Evolution
Traditional RSO production used naphtha or isopropyl alcohol — neither food-grade. Naphtha is complex petroleum hydrocarbon mixture that may contain benzene, toluene, and other toxic/carcinogenic compounds. Incomplete solvent purging leaves potentially harmful residues difficult to verify without analytical chemistry equipment.
Modern cannabis extraction uses food-grade ethanol or supercritical CO₂. These methods allow much more complete solvent removal, and finished products can be tested for residual solvents using validated analytical methods like headspace gas chromatography.
This evolution connects directly to product-quality discussion in our GENERAL KNOWLEDGE section: product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, and dose variability materially affect interpretation in real-world products [1][10][11][14].
For Logan County residents considering DIY extraction (which is illegal under Arkansas law for non-medical-card holders anyway), this safety education is critical. The fire risk alone in a rural setting — where emergency response times can be longer — makes solvent-based home extraction dangerous.
The Decarboxylation Question
Traditional RSO was fully decarboxylated. Heat from rice cooker evaporation (60-80°C for naphtha, ~82°C for isopropyl) converted essentially all THCa to delta-9 THC. Acidic cannabinoids abundant in raw cannabis — THCa, CBDa, CBGa — were lost as distinct compounds.
Our sublingual formula deliberately preserves THCa at 1,500 mg. This is intentional formulation choice informed by THCa evidence profile, which notes THCa itself does not produce psychoactive effects associated with THC but interpretation depends heavily on route, temperature, processing, and storage because THCa can convert to THC under heating or over time [12].
Terpene Loss in Traditional RSO
Terpenes are volatile aromatic compounds with relatively low boiling points. Most cannabis terpenes volatilize at temperatures between 21-157°C, with many abundant terpenes (myrcene, limonene, pinene) boiling below 180°C. Traditional RSO production destroyed terpenes two ways: dissolving them into solvent wash, then evaporating them off during high-heat solvent removal.
Traditional RSO was essentially cannabinoid-only product despite being derived from terpene-rich plant. Whatever aromatic, flavoring, or potentially bioactive terpene compounds source cannabis contained were lost in production.
Our formulas specify live terpenes at 5% with defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Each terpene has its own evidence profile in GENERAL KNOWLEDGE section. Entourage-effect literature provides theoretical framework for why preserving and including terpenes alongside cannabinoids may matter pharmacologically, even though robust human clinical proof of cannabis-specific entourage effects remains limited [20][29].
Evidence Standards Then and Now
Rick Simpson operated in pre-legalization, pre-lab-testing era. When he began making and distributing oil in early 2000s, cannabis was illegal in Canada and most of world. No regulatory framework, no standardized testing infrastructure, no legal pathway for clinical research on cannabis oil protocols, no peer-reviewed journals dedicated to cannabis therapeutics. Cannabis underground was only access point; personal experience was primary evidence currency.
Simpson’s methods reflected constraints of that era. His evidence was anecdotal. His production was unstandardized. His claims were untested formally. This is not necessarily moral failing — it’s description of environment in which he operated.
This document takes fundamentally different approach. GENERAL KNOWLEDGE section applies formal evidence hierarchy: human clinical evidence first, then systematic reviews and meta-analyses, then institutional summaries, then preclinical and mechanistic literature [1]-[29]. Every compound-level claim tied to specific peer-reviewed sources with evidence strength clearly labeled. Intent is to honor historical origin of RSO while committing to standards of modern cannabinoid science. Where Simpson relied on personal testimony, this document relies on published literature and institutional sources.
For Logan County readers, this means you can trust that when we say “the evidence shows,” we’re not guessing. We’re looking at the same studies your doctor would look at, and we’re telling you what they actually say — not what we wish they said.
Simpson’s Protocol vs. Modern Dosing Considerations
Simpson’s 60-gram/90-day protocol designed around crude, single-strain, THC-dominant extract with no standardized potency. Direct comparison between Simpson’s dosing recommendations and dosing with modern, standardized, multi-cannabinoid formulation is not straightforward — products are fundamentally different.
Key differences:
- Cannabinoid concentration: Our sublingual formula delivers 553 mg total active cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown and variable.
- Cannabinoid ratios: Simpson’s oil was approximately 60-90% delta-9 THC. Our formula distributes 16,590 mg total cannabinoids across CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), delta-9 THC (90 mg), CBN (750 mg), and CBC (750 mg) — completely different pharmacologic profile.
- Terpene presence: Simpson’s oil had no terpenes. Our formula includes live terpenes at 5%, which may influence absorption, effect, and tolerability.
- Delta-9 THC exposure: Simpson’s protocol at peak dosing delivered approximately 600-900 mg delta-9 THC per day. Our sublingual formula contains only 90 mg delta-9 THC in entire 30 mL bottle (3 mg per mL), making per-dose delta-9 THC exposure dramatically lower.
Future dosing guidance for OilWell products should be developed independently of Simpson’s protocol, informed by per-compound evidence in GENERAL KNOWLEDGE section and responsible titration principles accounting for safety profile of each individual cannabinoid.
For Logan County residents, this means: Do not follow Simpson’s protocol with our product. Our formula is fundamentally different and requires its own approach, detailed later in this guide.
References for This Section
RS1. Simpson R. Phoenix Tears: The Rick Simpson Story. Simpson RamaDur LLC; 2012.
RS2. Laurette C, director. Run From The Cure: The Rick Simpson Story . 2005. Distributed via phoenixtears.ca and online platforms.
RS3. Simpson R. Instructions and dosing information published on phoenixtears.ca. Multiple dates. Accessed March 2026.
RS4. Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436-444. PMID: 22555283.
RS5. Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197-203. PMID: 16804518.
RS6. National Cancer Institute. Cannabis and Cannabinoids (PDQ) — Health Professional Version. NIH/NCI. Updated 2024. Available at: https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq
ABOUT OILWELL CANNABIS AND THE OILWELL RSO FORMULA
The Origin of OilWell Cannabis (and Why a Texas Company Cares About Logan County, Arkansas)
OilWell Cannabis was founded by Colin Valencia in Houston, Texas. But Colin’s story starts in McAllen, Texas — right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. McAllen is a city of contrasts — vibrant culture yet deeply affected by poverty and limited opportunities outside retail and healthcare. Reynosa is industrial hub plagued by violence and cartel activity.
Colin’s childhood in McAllen exposed him to both opportunities and challenges of life along border. Early on, he learned to hustle, taking on risky work transporting items across border for various groups. Those experiences exposed him to complexities and dangers of that region. A lot of his best friends have been killed or are in prison because of associated dangers. He has faced every form of violence imaginable, both in streets and across border. By sixteen, one way or another, he had to leave home for good.
Despite dangers, Colin did not fall into darkest paths available, like selling harder substances. Instead, he focused on cannabis, seeing it as safer and more beneficial alternative. He grew up in traditional cannabis world long before legalization, learning plant intimately while operating in shadows. Over time, he transitioned from early risky ventures to creating legal, legitimate business in industry he believes in.
Colin later became formally trained software engineer and did custom development work for Baylor College of Medicine, one of most prestigious medical institutions in Texas Medical Center. That combination — deep cannabis plant knowledge plus medical-grade technical precision — defines OilWell’s approach.
In Logan County, where we know what it means to grow up hard and figure things out yourself, this origin story matters. We weren’t built by venture capitalists. We were built by someone who learned the plant because he had to, who learned precision because Bentley’s life depended on it, and who learned business because the alternative was watching people suffer when they didn’t have to.
Bentley’s Story: The Real Reason We Exist
The company’s origin story begins with a dog named Bentley. Bentley was more than just a pet — he was family, a companion who stood by Colin through toughest times. When Bentley fell seriously ill, veterinarians delivered verdict no pet owner wants to hear: euthanasia was only humane option. Bentley was paralyzed in his back legs. They said pain medications would destroy his internal organs, causing more pain and suffering. Choice was painful prolonged decline or immediate mercy killing.
But giving up on Bentley was not option. Colin had already faced too much loss and seen too much suffering. Bentley was fighter, just like him, and Colin was not ready to let him go. In desperate search for alternatives, he stumbled upon healing properties of CBD — through question that changed everything.
A kind-hearted rescue worker named Jessica asked Colin: “You’ve moved how many tons of weed and you’ve never heard of CBD?”
Colin had cannabis experience — but it was recreational. Getting high. He had never explored therapeutic and medicinal applications. Jessica’s question exposed blind spot that would become mission.
Determined to save Bentley, Colin learned to create CBD golden paste — specialized cannabinoid formula for pets. It was not cure, but it was lifeline — and it was hope. And that hope delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball to play. It was miracle. From paralyzed and facing euthanasia to fetching his ball. This was not placebo effect — dogs do not respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.
Bentley lived another ten years, passing naturally at age twenty. During those ten years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced. Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led him to CBC’s role in neurogenesis. Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.
Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. CBD alone could not address neurodegeneration and dementia and glaucoma and arthritis simultaneously. Minor cannabinoids like CBG, CBN, and CBC became critical as Bentley aged. Pharmaceutical precision mattered — Bentley’s life depended on formula accuracy, not guesswork.
Bentley’s journey was Colin’s entry into world of cannabis beyond just getting high. It became mission to create real solutions that help alleviate pain and suffering, not just for pets but for people. Bentley’s story is foundation of OilWell Cannabis, driving commitment to quality, innovation, and compassionate care.
For Logan County pet owners facing similar crises — maybe your hunting dog’s hips are failing, maybe your family’s companion is suffering — we know that pain. Bentley is why we published the CBD golden paste recipe for free, so any Logan County pet owner can make it today:
CBD Golden Paste Recipe for Pets — The Original Open-Source Formula
Ingredients:
- 1/2 cup organic turmeric powder
- 1 cup water
- 1/3 cup coconut oil (unrefined, organic)
- 1-2 teaspoons freshly ground black pepper (important for absorption)
- CBD oil (dosage depends on size and needs of pet; consult veterinarian)
Instructions:
- Mix turmeric and water in saucepan over low heat, stirring continuously until thick paste forms (7-10 minutes). Add more water if too thick.
- Add coconut oil and pepper. Stir until thoroughly mixed.
- Cool and transfer to jar with lid. Store in refrigerator up to two weeks.
- Add small amount of CBD oil to paste before giving to pet, adjusting dosage based on weight and health needs. Start low and increase gradually.
Serving suggestion: Mix small amount with pet’s food once or twice daily. Monitor for changes and consult veterinarian with concerns. Always consult veterinarian before starting new supplement regimen.
This recipe published for free demonstrates open-source pattern is foundational behavior, not marketing strategy. We gave away formula that saved Bentley before we gave away formula designed for people. Open-source ethos is not strategy — it’s character.
Colin’s Personal Battle: PTSD, Benzo Addiction, and Peace Gummies
Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey — notoriously difficult and dangerous — using cannabinoid knowledge developed keeping Bentley alive.
Peace Gummies formula became OilWell product created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, OilWell also offers Peace Gummies formula in vape form, which Colin personally uses to manage his insomnia and severe PTSD on ongoing basis. This is not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, discovery that cannabinoids work when pills do not.
In Logan County, where veteran community is strong and where many residents deal with trauma, chronic pain, and prescription dependence, this personal story matters. We don’t just sell these products. We survive on them.
Doctor-Trusted Formulas and ABC13 Recognition
Over time, therapeutic benefits of cannabis Colin discovered through efforts to save Bentley became core of his work. He developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. Focus has always been on making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.
ABC13 KTRK Houston — Houston’s number-one news source — featured Colin and OilWell Cannabis in seven comprehensive news segments spanning 2019 to 2023, covering Texas marijuana law, Delta-8 legal analysis, COVID-19 community health leadership, criminal justice reform, and cannabis business pioneering. Colin was repeatedly selected as primary industry expert for cannabis policy and product coverage in America’s fourth-largest city.
No other Houston cannabis operator appears with that frequency or across that breadth of subject matter during same period.
Colin’s Foundational Philosophy
Colin’s quote from first ABC13 feature in September 2019 captures OilWell philosophy: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have best possible version to base their opinions off of to give it fair shot as to whether it’s right or wrong for them.”
This quote appears multiple times throughout this document because it is seed of everything we became. Open-source formula publication, evidence-based research documentation, refusal to make unsupported claims — it all traces back to this principle.
OilWell Today: Licensed, Verified, Houston-Based
Today, OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). Company has been operating since 2019, generates approximately one million dollars in annual revenue, maintains near-5.0 Google rating, and is Texas DSHS licensed. Products are not mass-produced — they are carefully crafted with personal touch, from artwork on packaging to formulations inside. All artwork, formulations, and packaging created in-house in Houston, using only OilWell’s own recipes and ideas. Colin brings Houston grit, McAllen roots, and builder’s mindset to company, but posture stays simple: make products with intent, answer directly, and never pretend cannabis is right for everyone.
For Logan County customers, this operational credibility matters. We’re not anonymous online brand. We’re verifiable, licensed business with physical address, media record, and real revenue. When you order from us, you’re ordering from company that has survived and thrived in competitive market by doing things right.
The OilWell RSO Philosophy: Four Core Principles
Our RSO is not traditional Rick Simpson Oil. It is formulated, multi-cannabinoid product informed by RSO tradition but departing from it in deliberate, evidence-motivated ways designed to solve problems that limited Rick Simpson’s original vision.
Four core principles define our approach:
-
Accessibility over gatekeeping. No medical card required. Anyone age 21+ can purchase. We ship nationwide across United States and internationally to customers who verify local legality. Simpson believed medicine should be accessible to everyone; we built product and distribution model that makes that accessible legally. For Logan County residents who don’t qualify for Arkansas medical card or don’t live near dispensary in Fort Smith or Little Rock, this is critical.
-
Patient-controlled potency. THCa sold in acidic, non-psychoactive form. Customer decides whether to use raw for non-psychoactive benefits or decarboxylate into delta-9 THC for full psychoactive potency. Simpson believed patients should control their own medicine; we engineered product that puts that control in customer’s hands through chemistry rather than rhetoric.
-
Open-source formulas. We publish complete formulas publicly — every cannabinoid, every milligram amount, every percentage — so anyone who cannot afford product can source ingredients and make their own version. Simpson gave his oil away for free and taught people how to make it; we adapted that ethos for modern cannabinoid marketplace by selling professionally manufactured product and publishing recipe.
-
Evidence-informed, not evidence-overstating. GENERAL KNOWLEDGE section represents our commitment to honest education about what science actually says. Simpson operated without access to peer-reviewed literature or clinical trial data; we have that access and use it to distinguish between what is well-supported, what is emerging, and what is overstated.
Farm Bill Compliance and The THCa Legal Framework
The 2018 Farm Bill (Agricultural Improvement Act) legalized hemp and hemp-derived products containing less than 0.3% delta-9 THC by dry weight at federal level in United States. This legal framework is foundation of our RSO product design.
Our RSO Sublingual Oil contains only 90 milligrams delta-9 THC in entire 30 mL bottle — 3 milligrams per milliliter — well under 0.3% threshold. All cannabinoids in formula are hemp-derived. Product is legal under federal law and in most states.
THCa (tetrahydrocannabinolic acid) is acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at point of sale because it has not been converted to delta-9 THC.
Customer can decarboxylate THCa into delta-9 THC at home by heating oil at 260°F (125°C) for 45-60 minutes in oven-safe glass container. This converts 1,500 milligrams THCa into approximately 1,315 milligrams delta-9 THC. Combined with existing 90 milligrams delta-9 THC, this produces approximately 1,405 milligrams total delta-9 THC — giving product psychoactive potency comparable to traditional illegal RSO, entirely at customer discretion after purchase.
This means same product can function as non-psychoactive anti-inflammatory (used raw) or as full-potency psychoactive cannabinoid product (after home decarboxylation). Customer controls decision. Product is legal everywhere all component cannabinoids are legal, enabling international shipping to jurisdictions where hemp-derived products with less than 0.3% delta-9 THC are permitted.
Important legal notice: THCa converts to delta-9 THC when heated. Customers responsible for understanding and complying with local laws regarding cannabinoid products. We ship with full documentation, Certificates of Analysis, and receipts. International customers accept all customs and legal responsibility.
For Logan County residents, this creates unprecedented access. You don’t need medical card. You don’t need to drive to Fort Smith dispensary. You can order legally, have it shipped discreetly to your door in Paris or Booneville or wherever you call home, and you control whether it stays non-psychoactive for daytime use or becomes full-potency for nighttime relief.
The Decarboxylation Choice — Patient-Controlled Potency
Traditional RSO was always fully decarboxylated. Heat of solvent evaporation converted all THCa to delta-9 THC, leaving patient with no choice about psychoactivity — oil was always psychoactive.
Our sublingual formula contains 1,500 milligrams THCa in acidic, non-psychoactive form. This creates three distinct usage options:
Option 1 — Raw, no heat. All 1,500 milligrams stays as THCa — completely non-psychoactive. THCa evidence profile describes potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism [12]. Option compatible with work, driving, daytime use with zero psychoactive impairment. For Logan County residents who operate heavy equipment, drive trucks, or work jobs where impairment is not an option, this is game-changer.
Option 2 — Fully activated, home decarboxylation. Heating oil at 260°F (125°C) for 45-60 minutes in oven-safe glass container converts 1,500 milligrams THCa to approximately 1,315 milligrams delta-9 THC. Combined with existing 90 milligrams delta-9 THC, yields approximately 1,405 milligrams total delta-9 THC. Customer may also transfer controlled portion from original bottle into second empty oven-safe glass container, decarboxylating only what they intend to use and preserving remainder in raw THCa form.
Option 3 — Vape, auto-decarboxylation. RSO Vape Cartridge vaporizes at 400-450°F, instantly converting THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is fastest-onset RSO delivery method available.
Conversion chemistry: THCa has molecular weight of 358.47 g/mol. Conversion ratio is approximately 1 milligram THCa = 0.877 milligrams delta-9 THC after decarboxylation, reflecting loss of CO₂ molecule during reaction.
This design puts potency decision entirely in customer’s hands — aligning with Rick Simpson’s principle that patients should control their own medicine, but implementing that principle through actual product chemistry rather than one-size-fits-all approach.
Solvent-Free Production
Our RSO is not extraction product in traditional sense. It is formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents present in finished product.
This approach eliminates residual solvent risk that is one of most significant safety concerns with traditional RSO production, as discussed in Rick Simpson section.
Product uses organic MCT oil (medium-chain triglycerides) as carrier base. MCT oil is food-grade lipid carrier that facilitates cannabinoid absorption through sublingual tissue and provides neutral taste profile — significant improvement over tar-like consistency and solvent-residual odor of traditional RSO.
Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) available on request and accessible through our website.
For Logan County residents concerned about product purity — especially after Arkansas has seen its share of contaminated products in news — this testing transparency is non-negotiable. We show you what’s in the bottle, what’s not, and prove it with lab results.
The Broader OilWell Product Portfolio
Beyond RSO, OilWell Cannabis produces range of cannabinoid products, each developed from formulation knowledge Colin built over Bentley’s ten-year journey and his own experience with PTSD and benzo withdrawal.
Asshole Peach — Our most popular product. Asshole Peach is carefully formulated experience designed to provide euphoric, long-lasting sensation. Particularly favored by veterans for ability to relieve pain and PTSD symptoms without being overly aggressive.
Peace Gummies — Developed directly from Colin’s own experience with PTSD and benzodiazepine addiction. Peace Gummies helped him quit Xanax cold turkey. Formula also available in vape form for quick relief — Colin personally uses vape to manage his insomnia and severe PTSD on ongoing basis.
Custom creations — OilWell offers custom-made products tailored to specific needs of individual customers. Whether involves specific cannabinoid ratios, particular delivery formats, or formulations for unique health circumstances, we design targeted products on request. This includes formulations for vegans, diabetics, and those with specific dietary or health needs.
Two Product Formats
We offer RSO formula in two delivery formats, each designed for different use cases and pharmacokinetic profiles.
RSO Sublingual Oil — $129.99
- 30 mL bottle (1 fl oz)
- 16,590 mg total cannabinoids (553 mg per mL)
- Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
- Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
- Organic MCT oil base
- Graduated dropper for precise dosing in 0.1 mL increments
- Onset: 15-45 minutes (sublingual absorption through oral mucosa)
- Peak effects: 1-2 hours
- Duration: 4-6 hours
- Bioavailability: 13-19% (sublingual route partially bypasses first-pass liver metabolism)
- Approximately 40-60 doses per bottle depending on serving size
RSO Vape Cartridge — $49.99
- 1-gram cartridge
- 900 mg+ total cannabinoids
- Same six-cannabinoid ratio as sublingual formula
- Live terpenes at 5%+
- 510-thread universal battery compatibility
- Onset: 1-2 minutes (fastest cannabinoid delivery method)
- Peak effects: 10-15 minutes
- Duration: 2-4 hours
- Bioavailability: 10-35% (variable, dependent on inhalation technique)
- Automatic THCa decarboxylation at vaping temperature (400-450°F)
Complete RSO Guide available on our website with science, competitive analysis, protocols, and ordering information.
When to Use Each Format
| Use Case | Recommended Format | Rationale |
|---|---|---|
| Fast relief (acute pain, nausea, panic) | Vape | 1-2 minute onset |
| Sustained relief (chronic pain, sleep) | Sublingual | 4-6 hour duration |
| Maximum bioavailability | Sublingual | 13-19% absorption |
| Portability and discretion | Vape | Compact, no measuring required |
| Precise dosing control | Sublingual | Graduated dropper in 0.1 mL increments |
| Daytime non-psychoactive use | Sublingual (raw, no heat) | THCa stays inactive, zero impairment |
| Nighttime psychoactive use | Sublingual (decarbed) or Vape | Activated THCa + delta-8 THC |
Competitive Comparison — OilWell RSO vs. Alternatives
OilWell RSO vs. Arkansas Medical Cannabis (AMC) Dispensary RSO
| Dimension | AMC Dispensary RSO | OilWell RSO |
|---|---|---|
| Cannabinoid profile | THC-only or limited ratios | 7 cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC |
| CBG content | 0-50 mg typically | 3,000 mg |
| CBN content | 0-20 mg typically | 750 mg |
| CBC content | Usually 0 mg | 750 mg |
| Patient-controlled potency | No — always psychoactive if THC-dominant | Yes — THCa non-psychoactive until heated by customer |
| Access requirements | Arkansas medical card with qualifying condition | Age 21+ only, no medical card required |
| Qualifying conditions | Cancer, PTSD, ALS, MS, severe arthritis, etc. | None required |
| Delivery | Must travel to dispensary (Fort Smith, Little Rock, etc.) | Ships directly to Paris, Booneville, Magazine, anywhere in Logan County |
| Price per total cannabinoids | ~$60-80 for 500-600 mg THC | $129.99 for 16,590 mg total cannabinoids |
| Lab testing | Required by Arkansas law | Full panel testing, COAs available |
| Legal for Logan County residents | Only with medical card | Yes — Farm Bill compliant |
OilWell RSO vs. Hemp CBD RSO (e.g., national brands)
| Dimension | Hemp CBD RSO (typical 10 mL, 1,000 mg) | OilWell RSO (30 mL, 16,590 mg) |
|---|---|---|
| Total cannabinoids | 1,000 mg | 16,590 mg |
| CBD content | ~950 mg | 4,500 mg |
| CBG content | 0-50 mg | 3,000 mg |
| CBN content | 0-20 mg | 750 mg |
| Delta-8 THC | 0 mg | 6,000 mg |
| THCa (convertible) | Minimal | 1,500 mg (≈1,315 mg delta-9 THC when heated) |
| Psychoactive option | No meaningful effect | Yes — via THCa decarboxylation and delta-8 THC |
| Price | $40-50 | $129.99 |
| Value per mg cannabinoid | ~$0.05/mg | ~$0.008/mg |
OilWell RSO vs. Traditional Illegal RSO
Refer to table in Traditional RSO vs. Modern Formulated RSO section above for full eleven-dimension comparison.
Condition-Specific Usage Context
Important Disclaimer: Following usage contexts informed by cannabinoid research cited in GENERAL KNOWLEDGE section and by OilWell formulation rationale. Not medical prescriptions, not FDA-approved treatment protocols, not substitute for professional medical care. These products have not been evaluated by Food and Drug Administration and not intended to diagnose, treat, cure, or prevent any disease. Always consult qualified healthcare provider before using cannabinoid products, especially if you have medical condition, are taking medications, are pregnant or nursing, or have health concerns. Do not operate vehicles or machinery while under influence of psychoactive cannabinoids.
Chemotherapy-Related Nausea and Appetite Support
- Pre-chemo: 0.5-1.0 mL sublingual approximately 1 hour before treatment
- Acute breakthrough nausea: 2-3 vape puffs for immediate relief (1-2 minute onset)
- Post-chemo: 0.5 mL sublingual every 6 hours as needed
- Sleep support during treatment: 1.0-2.0 mL sublingual before bed (delivers 25-50 mg CBN)
- Evidence context: delta-8 THC antiemetic evidence [9], delta-9 THC nausea/vomiting evidence [1][13], CBD anxiolytic buffering [3]
For Logan County residents traveling to UAMS in Little Rock or Oklahoma City for cancer treatment, having product that can be shipped directly to your home and used according to your treatment schedule is major advantage over dispensary-only access.
Chronic Pain (Fibromyalgia, Arthritis, Neuropathy)
- Daytime: 0.3-0.5 mL raw sublingual — provides anti-inflammatory cannabinoid exposure without psychoactive impairment
- Nighttime: 0.5-1.0 mL decarboxylated sublingual — combines pain relief with CBN sleep support
- Breakthrough pain: Vape as needed for rapid onset
- Evidence context: CBD pain evidence [4], delta-9 THC pain evidence [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]
In Logan County’s aging population and among those who’ve done physical labor for decades, chronic pain is epidemic. Many have cycled through prescription NSAIDs, gabapentin, or worse. Our multi-cannabinoid approach offers alternative that doesn’t require daily opioids.
Sleep Support
- Before bed: 1.0-2.0 mL sublingual
- At 2.0 mL, delivers 50 mg CBN — dosage level investigated in 2024 sleep literature
- At 1.0 mL, delivers 25 mg CBN — above 20 mg threshold associated with reduced sleep disturbance in published research
- Evidence context: CBN sleep evidence [16][17], cannabis and sleep review literature
Logan County’s quiet nights are one of its blessings, but not if you’re lying awake at 3 AM with racing thoughts or pain. Our sleep support protocol designed for people who’ve tried everything else.
Anxiety and Stress
- Daytime functional relief: 0.3 mL raw sublingual — CBD and CBG address anxiety-related pathways without psychoactive impairment
- Nighttime: 1.0 mL sublingual — full cannabinoid profile including CBN for sleep architecture
- Evidence context: CBD anxiety evidence [3], CBG pharmacology [7][8], limonene entourage-effect evidence [20]
In tight-knit Logan County communities, anxiety often goes unspoken. We talk about “nerves” or “stress.” There’s no shame in it. Our daytime raw option lets you manage symptoms while staying completely functional for work, family, and community responsibilities.
General Titration Principle: Start low, go slow. Begin with 0.25-0.5 mL sublingual and assess effects over 2-3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors.
Delivery and Global Accessibility
OilWell operates only same-day RSO delivery system in Houston. Beyond Houston, we ship nationwide and internationally. For Logan County residents, this means access to clinical-strength, multi-cannabinoid RSO without leaving your driveway.
Houston Same-Day Delivery
| Zone | Coverage | Delivery Fee | Typical Turnaround |
|---|---|---|---|
| Texas Medical Center | All 60+ TMC institutions (MD Anderson, Memorial Hermann, Methodist, Texas Children’s, etc.) | FREE | 2-4 hours |
| Inner Loop (610) | Downtown, Montrose, Heights, River Oaks, etc. | $5 | 2-4 hours |
| Within Beltway 8 | Bellaire, Memorial, Spring Branch, etc. | $10 | 3-5 hours |
| Greater Houston suburbs | Katy, Sugar Land, etc. | $15 | 4-6 hours |
| Extended region (60 miles) | Galveston, Baytown, etc. | $20-25 | Same-day if ordered before 2 PM |
Free delivery to Texas Medical Center — world’s largest medical complex with over 10 million patient visits annually — reflects commitment to accessibility for patients who need it most.
Nationwide Shipping
- All 50 states where Farm Bill-compliant products legal
- USPS Priority Mail (2-3 business days), FedEx and UPS Ground (3-5 business days)
- Discreet packaging with no cannabis branding visible
- Tracking provided for all orders
- Temperature-stable packaging for summer shipments
- Signature-required option available
For Logan County residents in rural areas where mail delivery may be to PO boxes or cluster boxes, we accommodate. Just specify in order notes.
International Shipping
We ship internationally and have delivered to multiple countries across multiple continents. THCa legal framework makes this possible: because product contains less than 0.3% delta-9 THC at point of sale, it meets definition of hemp-derived product under 2018 Farm Bill and is shippable to jurisdictions with compatible hemp laws.
- All international packages include full documentation, Certificates of Analysis (COAs), and receipts for customs
- Minimum flat-fee shipping applies; excessive international costs billed to customer
- Customer responsible for verifying legality in their jurisdiction and accepts all customs and legal risk
- Contact: (832) 416-2816 or [email protected]
In Logan County, you might have family overseas — a veteran son in Germany, a daughter working in Australia — who need access to these formulations. We can ship to them legally, completing piece of Rick Simpson’s vision that prohibition made impossible during his lifetime.
OilWell’s PANDEM1C SEO technology — proprietary system with 14 million distinct geopolitical locations in database and over 300 AI models — drives organic search visibility across six continents, making OilWell products discoverable to international patients searching for RSO in their own language.
How OilWell Formulas Connect to Evidence in This Document
Every cannabinoid in OilWell formula — CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC — has its own evidence profile in GENERAL KNOWLEDGE section. Every terpene — limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene — covered with preclinical and review-level evidence.
Formulas published later in this document are not standalone product listings. They are anchored to per-compound evidence summaries explaining what is well-supported by human clinical data, what is emerging from review and preclinical literature, and what is overstated relative to current evidence base. Where OilWell RSO guide page makes specific research claims about individual cannabinoids or terpenes, this document provides source evaluation context — same peer-reviewed citations, same evidence-tier assessments, same cautious interpretation framework.
GENERAL KNOWLEDGE section’s evidence hierarchy, overstatement warnings, and safety notes apply equally to OilWell products. This document does not exempt OilWell from same evidence standards applied to broader cannabinoid field. That is intentional. Our position — as stated by Colin Valencia in 2019 — is that people deserve best possible version of information so they can give it fair shot and decide for themselves whether it’s right or wrong for them. This document is research foundation for that position.
OilWell Cannabis is more than brand — it is promise to customers that we will always strive to deliver best, most thoughtful cannabis products available. We are not here to follow trends. We are here to set them. And as company continues to grow, focus remains on maintaining same level of integrity, creativity, and commitment that defined it from day Bentley got up, walked across room, and brought his ball to play.
MEDIA RECOGNITION AND COMMUNITY IMPACT
Colin Valencia — Houston’s Go-To Cannabis Authority (And What That Means for Logan County)
Between September 2019 and April 2023, ABC13 Houston (KTRK) — ABC affiliate serving fourth-largest city in United States — featured Colin Valencia and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different ABC13 reporters sought Colin out across those years: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator appears with that frequency or across that breadth of subject matter during same period.
For Logan County residents evaluating credibility of online cannabis company, this matters. Mainstream media validation from major-market ABC affiliate establishes credibility that no amount of marketing can replicate. When ABC13 needed to explain new cannabis product, legal change, or community health initiative, they called Colin. That is recognition earned through expertise, not purchased through PR.
These features document consistent pattern. When ABC13 needed to explain Delta-8 legality to its audience, it called Colin. When state agency reversed course on Delta-8 overnight, it called Colin. When sitting president announced marijuana pardons and station needed someone who personally lived with cannabis conviction to put it in context, it called Colin. When station wanted to tell story of growing industry on 4/20, it was Colin’s hemp field and voice that anchored report.
What follows is complete, chronological record of each feature — every quote preserved exactly as published, every contextual detail documented, every connection to broader OilWell story and mission noted, and full article content from each ABC13 report preserved for reference.
Feature: Texas CBD businesses booming as industry continues to evolve — September 15, 2019
Source: ABC13 Houston (KTRK)
Headline: “Texas CBD businesses booming as industry continues to evolve”
Reporter: Tom Abrahams
Published: Sunday, September 15, 2019
YouTube Clip: OilWell CBD Oil Houston ABC News KTRK Interview Clipped
This is earliest documented ABC13 feature on OilWell — and origin point of foundational philosophy that drives everything in this document.
Full Article Content
HOUSTON, Texas (KTRK) — You can spot the signs in almost any neighborhood. CBD has turned into a booming business over the past few months, with entrepreneurs pitching the product for every member of the family, even the pets.
Amanda Field owns Republic Aerial Yoga on Houston Avenue in downtown. Her clients visit her studio for their health, to educate themselves, and to lessen their aches and pains.
“I’ve had people tell me that they’ve come to two classes and their back pain is gone.”
— Amanda Field, Republic Aerial Yoga owner
But for Field, it’s not just about yoga. Many of her clients combine the exercise with cannabidiol, a hemp-based product better known as CBD.
“It partners so well with yoga.”
— Amanda Field
Krystal Burns is one of those clients. She said she injured her back in an accident and had surgery. She said she was in constant pain and said doctors wanted to prescribe her opioids. Burns refused, and after learning about CBD from Field, she says she’s now a believer.
“I wouldn’t be able to function without it. It easily relaxes my muscles, it helps me sleep. I don’t have to worry about addiction.”
— Krystal Burns, CBD user and yoga client
Jim Bagley is another believer. He owns Linear Salon in the Heights. He says he and his wife use CBD and sell it in their shop.
“I was having trouble sleeping, restless in the mid-morning probably. I truly feel that there is benefits to it. I hope it’s not a trend. I think that the benefits I’ve received personally, hopefully I’ll be able to get my clients to enjoy the same benefits I’ve received.”
— Jim Bagley, Linear Salon owner
CBD use was in a legal, gray area in Texas until House Bill 1325, which Gov. Greg Abbott signed into law in June. The bill changed the legal definition of marijuana and hemp production in Texas. As a result, CBD as a business is booming. The product, however, cannot have .3 percent of THC, the chemical that makes you high.
That past summer, four local district attorneys announced they would not file criminal cases involving marijuana or cannabis unless testing proved the THC concentration was higher than .3 percent.
Dorral Marsenburg sells his Booman cannabis in a smokable form and says the industry is in its infancy in Texas.
“In a typical week, I’ll go through a half a pound selling grams. I say two years from now, it’ll be multi-billion dollar operation. I honestly believe that because it’s 100 percent legal, and besides the THC, it’s healthy for you also.”
— Dorral Marsenburg, Booman cannabis
Colin Valencia, who runs OilWell CBD, a local wholesaler, says it’s an evolving industry.
“It’s a lot of educating people, but not over-promising people. I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”
— Colin Valencia, OilWell CBD
The FDA is still examining the actual health benefits and ways to regulate the content of cannabis products. In May, it held its first ever CBD hearings and states it is committed to sound, science-based policy.
Related: New hemp law means no criminal charges for some pot possession cases, Harris County DA says | CBD Oil: What you need to know
Video Description: “CBD TAKEOVER: The industry continues to grow with entrepreneurs pitching the product for every member of the family, including pets!”
Analysis
That Colin quote — from 2019, years before formulas in this document were published — is seed of everything OilWell would become. Open-source formula publication, evidence-based research documentation, refusal to make unsupported claims: it all traces back to this principle. Video segment’s description noting CBD was being pitched “for every member of family, including pets” is early indicator of broad-spectrum consumer education approach Colin would continue to build. Clipped version of Colin’s interview from this broadcast was separately uploaded to YouTube as standalone demonstration of OilWell’s media presence on major network affiliate.
Feature: Entrepreneur creates direct-to-consumer business ahead of marijuana decriminalization efforts — March 22, 2021
Source: ABC13 Houston (KTRK)
Headline: “Entrepreneur creates direct-to-consumer business ahead of marijuana decriminalization efforts”
Reporter: Tom Abrahams
Published: Monday, March 22, 2021
Full Article Content
HOUSTON, Texas (KTRK) — The proof is evident that decriminalizing cannabis doesn’t increase crime rates, according to Senate Majority Leader Chuck Schumer. It’s a basis as to why there is a renewed push to decriminalize cannabis at the national level.
One entrepreneur is already coming up with a unique way to get cannabis directly to the customer.
It’s not a taco truck. In fact, Jonathan Pina’s concept for High Maintenance Edibles is not like any other mobile vendor you’ve likely seen.
“We partner with private companies, bars restaurants, parking lot owners and we show up at places around Houston and provide our products.”
— Jonathan Pina, High Maintenance Edibles
His concept got a lift from Oil Well. A company that specializes in hemp based products legal in Texas and run by owner Colin Valencia. He said the tide is turning and more and more people accept legitimate uses for cannabis based products. The stigma is slowly disappearing.
“People think that everyone just wants to get high and it’s about giggling and things like that, and there’s nothing wrong with that. But that’s a different version of therapy, and people are looking for things to help them with real pain. Pain comes in a lot of different forms.”
— OilWell CBD’s Colin Valencia
It’s getting a step closer to both decriminalization and legalization. While Texas may be far from legal recreational use, Congress may make its own move.
This week, Schumer and Senators Corey Booker of New Jersey and Ron Wyden of Oregon announced forthcoming legislation on Capitol Hill.
“When states decriminalized or legalized, all the horrible stories that people said crime rates would go up, people’s drug use would go up, never materialized.”
— Senator Chuck Schumer
The three of them cited the failed war on drugs, that veterans and people of color are disproportionately punished for use with excessive fines or jail time. There are already 15 states that have passed ballot measures or have laws allowing recreational use.
“If people want to use it and it doesn’t do harm, just like Oregon showed, let them do it.”
— Senator Chuck Schumer
For those in the business and on its forefront in Texas, entrepreneurs like Pina believe it’s long overdue. But in Austin, they are not there yet. Despite loosening restrictions and a spate of bills this session, full legalization is not as likely as it might be in Washington.
Related: Texas lawmakers hope to expand medical marijuana programs this legislative session | Texas’ medical marijuana program is one of the most restrictive in the country
Video Description: Decriminalizing cannabis doesn’t increase crime rates, according to Senate Majority Leader Chuck Schumer. He said there’s renewed push to decriminalize marijuana at national level, but how will this impact Texas?
Analysis
Tom Abrahams returned to OilWell for this feature, establishing Colin’s role not just as business operator but as ecosystem builder who helped other entrepreneurs like Jonathan Pina enter legal cannabis space. Colin’s therapy quote — “pain comes in a lot of different forms” — went deeper than any prior interview into therapeutic dimension, and national decriminalization context (Schumer, Booker, Wyden) positioned OilWell at intersection of Texas innovation and federal momentum.
Feature: What is Delta 8 THC and why is it considered legal weed in Texas — May 24, 2021
Source: ABC13 Houston (KTRK)
Headline: “What is Delta 8 THC and why is it considered ‘legal weed’ in Texas?”
Reporter: Steve Campion
Published: Monday, May 24, 2021
Full Article Content
A lush green plant is creating buzz in Texas as the cannabis industry is booming, despite federal and state law banning marijuana.
The 2018 Farm Bill legalized hemp plants, which contain extremely low concentrations of the psychoactive compound Delta 9 THC. That’s the THC typically found in pot which gives users a high. Entrepreneurs are now extracting any compound they want from the hemp plants and have narrowed in on Delta 8 THC. They’re making products including edibles, tinctures, and smokables with it. Delta 8 THC isn’t as strong as Delta 9 THC.
You’ll likely spot the Delta 8 products in stores around the Greater Houston like at HydroShack Hydroponics on West 20th Street in The Heights which sells Oilwell Cannabis products.
“Demand is like this,” . “People are grateful that we’re here and selling it. Very grateful. That’s the feeling I get.”
— Chris Powers, owner of HydroShack Hydroponics
Colin Valencia with Oilwell said the products offer therapeutic benefits at affordable prices. Valencia remained unabashed by his enthusiasm for them. He offered a pretty blunt explanation about how some might use Delta 8.
Steve Campion (ABC13): “Why would someone want to smoke that?”
Colin Valencia: “I don’t give a sh** if it’s wrong to say you’ll get high off it. Maybe you want to get high.”
“Delta 8 hasn’t been looked at, so we just don’t know. We’re gathering data now, so the more people who use, the more information we’ll have. You probably don’t want to be a guinea pig just yet. We know Delta 9 THC is habit forming. Delta 8 THC is likely to have that property as well. If you’re using it, you may find it’s harder to stop than you thought.”
— Dr. Michael Weaver, UTHealth/UT Physicians addictions specialist
ABC13 then asked him if he would advise anyone to take it.
“I think there is not enough information to say it’s good to try. The safest thing I can say is we don’t know enough about it to make a recommendation. Don’t try it until we know more.”
— Dr. Michael Weaver
Experts said using Delta 8 THC will likely lead to failed drug tests for employees.
Heather Fazio with Texans for Responsible Marijuana Policy told ABC13 some lawmakers already want to ban Delta 8 products in the state. She said the conversation should be on regulation, not prohibition.
“We’re seeing the market become innovative. Entrepreneurs getting creative with the ways they can abide by the law and still provide their customers with the product they would like. What we’re looking at here is simply the result of supply and demand. We know there is a demand for cannabis products in the state of Texas. Unfortunately, our state continues to deprive legitimate business owners of the opportunity to sell these products in a regulated way, products that are tested that are labeled appropriately.”
— Heather Fazio, Texans for Responsible Marijuana Policy
DEA Statement:
Delta 8 THC was added to the controlled substances list in August 2020 on an interim basis while pending final disposition. As DEA is currently undergoing the rulemaking process regarding the implementation of the Agriculture Improvement Act of 2018 – which includes the scope of regulatory controls over marijuana, tetrahydrocannabinols, and other marijuana-related constituents – we would be unable to comment on an any impact in legality of tetrahydrocannabinols, Delta 8 included, until the process is complete. We are in the process of reviewing thousands of comments and do not speculate on what could happen as a result.
Related: Texas’ medical cannabis program could expand under bill OK’d by House
Video Description: This lush green plant is creating buzz in Texas. ABC13 reporter Steve Campion investigated what it is, its effects on the body and whether or not it is legal in Texas.
Analysis
This investigative feature by Steve Campion became one of most widely referenced ABC13 cannabis segments. Exchange between Campion and Colin — “Maybe you want to get high” — became one of Colin’s most iconic media moments: radical honesty on mainstream television with expletive preserved by network. Piece balanced Colin’s unapologetic stance with Dr. Weaver’s medical caution and Heather Fazio’s regulatory advocacy, and full DEA statement documented federal ambiguity that allowed market to exist. This article cross-referenced by ABC13 in multiple subsequent features and served as foundational explainer that later Delta-8 coverage built upon.
Feature: Houston CBD shop giving away free products to those who get COVID vaccine — August 20, 2021
Source: ABC13 Houston (KTRK)
Headline: “Houston CBD shop giving away free products to those who get COVID vaccine”
Reporter: KTRK Staff
Published: Friday, August 20, 2021
Full Article Content
HOUSTON, Texas (KTRK) — A Houston CBD shop is offering a unique incentive to get people vaccinated.
According to an Instagram post published on Wednesday, OilWell CBD, which specializes in hemp-derived CBD and THC products, said it wants to give away 1,000 pieces of product to those who get vaccinated after Aug. 18.
The company is offering to give away 1,000 special edition caviar pre-rolls, which according to its website, is a THC-infused product coated with oils and hash kief, a more refined form of cannabis. OilWell sells these items for $34.99, according to its website.
The company said you must provide proof of vaccination along with a photo ID.
The giveaway will take place starting Monday at noon at HydroShack Hydroponics on West 20th Street in The Heights, which sells OilWell products.
“We just want Houston to be as healthy as possible. We’re not doctors. We’re not experts on this . We don’t have any political agenda. Come and participate if it’s right and safe for you and your loved ones!”
— OilWell Instagram post
The company later posted another Instagram post saying it’s been in contact with the city of Houston to help more people get vaccinated.
“[We’re] trying to get the city behind me to help as many people as we can. I really want to help things.”
— OilWell follow-up Instagram post
The 2018 Farm Bill legalized hemp plants, which contain extremely low concentrations of the psychoactive compound Delta-9 THC. That’s the THC typically found in marijuana that gives users a high. Entrepreneurs are now extracting any compound they want from the hemp plants and have narrowed in on Delta-8 THC. Companies like OilWell are now making products such as edibles, tinctures, and smokables.
Note: The video above is from an ABC13 report published on May 24 in which we spoke with OilWell CBD about Delta-8 THC products and why it’s considered “legal weed” in Texas.
Video Description: This lush green plant is creating buzz in Texas. ABC13 reporter Steve Campion investigated what it is, its effects on the body and whether or not it is legal in Texas.
Analysis
This feature documented OilWell’s most significant community health initiative — approximately $35,000 in product (1,000 caviar pre-rolls at $34.99 each) donated to encourage COVID-19 vaccination. Pre-rolls were collaboration product: The Game x OilWell Cannabis Delta 8 Caviar Comet Rock Pre-Rolls. Giveaway hosted at same HydroShack Hydroponics retail partner featured in Delta-8 segment months earlier. OilWell’s coordination with city of Houston to amplify vaccination effort demonstrated company’s community orientation was not hypothetical — when public health crisis required action, company committed real product and real coordination with city government, with no political strings attached.
Feature: Texas ban over once legal hemp product Delta 8 raises questions over legality — October 19, 2021
Source: ABC13 Houston (KTRK)
Headline: “Texas’ ban over once legal hemp product, Delta 8, raises questions over legality”
Reporter: Shelley Childers
Published: Tuesday, October 19, 2021
Full Article Content
HOUSTON, Texas (KTRK) — Inside the Oil Well dispensary in southwest Houston, owner Colin Valencia said he has removed all of his Delta 8 products.
“It’s going to be a surprise to a lot of people.”
— Colin Valencia
It’s a surprise because when ABC13 met Valencia earlier this year, Delta 8 products were his best sellers.
“It was a prime seller and a prime interest of customers, and they really enjoyed the benefits of it.”
— Colin Valencia
Delta 8 is a cannabinoid sold as edibles, tinctures, pills, topical ointment, you can smoke it and vape it. Most CBD dispensaries and vape stores sell it.
“We’ve heard of vets with PTSD who use these products for things like anxiety, dealing with stress and emotions. There’s also people who use these products for sleep regulation. Our association recently, during the state session, actually estimated that the Delta 8 market is around about $50 million in Texas.”
— Zachary Maxwell, Texas Hemp Growers
Delta 8 is derived from hemp cannabis. It took off after the 2018 Farm Bill legalized hemp production federally. It is a THC product and, up until last week, it was never explicitly listed on the state’s controlled substance list.
“A lot of the industry has been operating under the assumption that Delta 8 is legal or that it exists inside of this gray area, and unfortunately, as we are learning, this is not the case. These products have in fact been illegal since the beginning of this year.”
— Zachary Maxwell
On Oct. 15 the Texas Department of State Health Services posted an update on their Consumable Hemp Program page saying in part, “All other forms of THC, including Delta 8 in any concentration and Delta 9 exceeding 0.3%, are considered Schedule I controlled substances.”
“And if you’re caught with as much as a Delta 8 vape cartridge or even a package of gummies, you could be looking at a felony offense punishable up to two years in prison and a fine up as much as $10,000.”
— Zachary Maxwell
He says the state made no other formal notification to the more than 2,000 licensed CBD operators including Valencia, who has been trying to spread the word himself.
“So those people are now, because they didn’t know, shipping Schedule 1 narcotics, and people are receiving it.”
— Colin Valencia
ABC13 reached out to Texas DPS to find out if and how the state will enforce this-known ban. They were still awaiting a response.
ABC13 spoke with the Texas DSHS to ask about the updated verbiage on Delta 8. A spokesperson says Delta 8 has always been illegal because it is a THC cannabinoid. She could not speak to how the Delta 8 market was allowed to publicly blossom and thrive while being considered illegal. She told ABC13 that the hemp industry asked DSHS for clarification on its legality which prompted the announcement last Friday.
While both men worry for the small businesses who rely on Delta 8 products for the majority of sales, they remain optimistic about the future of cannabis in Texas.
“It’s disappointing, but I’m not going to lose my customers and business are going to want our expertise on how to continue thriving in the industry.”
— Colin Valencia
Video Description: A cannabis businessman says Texas’ recent move on making hemp products illegal is “dangerous.”
Analysis
This feature captures defining moment in OilWell’s story. Just two months after COVID vaccine giveaway, legal landscape shifted dramatically overnight. Shelley Childers went directly to OilWell dispensary and found Colin had already removed all Delta-8 products from shelves — proactively, before enforcement began, and before most of industry even knew change had happened. Colin had been trying to spread word himself to other operators who were unknowingly shipping what had overnight become Schedule I narcotics. Zachary Maxwell’s context — veterans with PTSD, $50 million Texas market, felony penalties for single vape cartridge — made stakes viscerally clear. Texas DSHS told ABC13 that Delta-8 “has always been illegal” but could not explain how market had been “allowed to publicly blossom and thrive while being considered illegal.” Willingness to absorb major revenue loss, act ethically ahead of enforcement, and position company as expert guide for industry in crisis rather than victim of regulation — that is OilWell’s character.
Feature: Biden marijuana pardon — experts weigh in on why Texas won’t see impact — October 7, 2022
Source: ABC13 Houston (KTRK)
Headline: “Experts weigh in on why Texas won’t see impact in accordance with Biden’s pardon announcement”
Reporter: Nick Natario
Published: Friday, October 7, 2022
Full Article Content
HOUSTON, Texas (KTRK) — President Joe Biden is planning to pardon thousands of Americans convicted of simple possession of marijuana, but Texas will not see much of an impact.
The owners of Oilwell Cannabis are preparing to debut their latest idea: A vending machine that will be filled with legal cannabidiol, or CBD, products.
The shop owner, Collin Valencia, has previously faced charges for marijuana possession.
“You face challenges with housing, loans, and banking, I mean with about everything.”
— Colin Valencia
Soon, select others won’t face those challenges after the president’s announcement.
“I would love to see people not get hurt for this anymore.”
— Colin Valencia
The pardon doesn’t impact Valencia. As legal expert Steve Shellist explains, this will only apply to certain federal convictions.
“If someone is currently stripped of rights via a state prosecution or a state conviction, they’re going to get no relief from this.”
— Steve Shellist, legal expert
He said a pardon allows people to carry a gun or avoid deportation.
“It reinstates rights that were stripped away, but it does not remove it from their record.”
— Steve Shellist
The pardon applies to about 6,500 people. Experts at Rice University said that there were 300,000 marijuana-related arrests at the state level last year. President Biden urged governors to do the same with state charges.
A spokesperson for Governor Greg Abbott sent ABC13 a statement that read:
“Texas is not in the habit of taking criminal justice advice from the leader of the defund police party and someone who has overseen a criminal justice system run amuck with cashless bail and a revolving door for violent criminals.”
— Governor Greg Abbott’s spokesperson
On social media, Abbott’s opponent Beto O’Rourke said, “When I’m governor, we will finally legalize marijuana in Texas and expunge the records of those arrested for marijuana possession.”
“Governors do not have the power to pass legislation unilaterally. It has to go through the Texas Legislature, and the Texas legislature for at least the next two or four years is going to have a Republican majority.”
— Mark Jones, Rice University political science professor
Don’t expect to see marijuana legalization in the upcoming session. However, it doesn’t mean the matter won’t be discussed.
“The most we’ll see in 2023 is decriminalizing marijuana and medical marijuana. We’re not going to see legalization. That’s for sure.”
— Mark Jones
Related: Biden pardons thousands convicted for ‘simple possession’ of marijuana
Video Description: There were 300,000 marijuana-related arrests last year in the state of Texas, but the pardon applies to about 6,500 people, a legal expert explained.
Analysis
This feature brought most personal dimension of Colin’s story into public view. Article opened with OilWell CBD vending machine debut — retail innovation extending product accessibility beyond traditional dispensary hours — and then revealed that Colin has previously faced charges for marijuana possession. That personal history transforms entire media record. Every feature, every quote about therapy, about education, about not selling snake oil — all carry additional weight when you understand person saying it has personally experienced consequences of cannabis criminalization. Political context (300,000 state arrests vs. 6,500 pardons, Abbott vs. O’Rourke, Mark Jones’s analysis) captured gap between federal gestures and Texas reality. Colin is not outside entrepreneur who saw business opportunity. He is someone who lived consequences and built legal business to prove industry could operate with integrity, transparency, and community benefit.
Feature: Marijuana industry getting creative as Texas laws continue to change — April 21, 2023
Source: ABC13 Houston (KTRK)
Headline: “‘I want it to be legalized’: Marijuana industry getting creative as Texas laws continue to change”
Reporter: Nick Natario
Published: Friday, April 21, 2023
Full Article Content
HOUSTON, Texas (KTRK) — On April 20, some Texas lawmakers and those in the marijuana industry are celebrating as changes could be coming with the drug.
The cannabis industry has changed in Texas, and new laws have allowed those in the industry to get creative.
“I want it to be legalized. I’m just saying that’s a very hyped conversation. If you really look at what’s here now, there’s nothing you could show me that I could accomplish with what literally we have right now.”
— Oilwell Cannabis owner Colin Valencia
Valencia grows something that looks like marijuana, but he says it’s not illegal. It’s hemp — a product the state allows and one that gives him the ability to create all kinds of products.
“Right now is actually a pretty – like Renaissance – pretty important time that should be enjoyed now.”
— Colin Valencia
As far as legal marijuana, it’s still restrictive in Texas. To use it, marijuana needs to be prescribed. There are currently around 50,000 Texans registered, but experts say only about 10,000 actively use medical marijuana.
“By comparison to Florida, which is two-thirds the size of Texas, they have 20 million people, and we have 30 million people, and they have 700,000 patients.”
— Nico Richardson, Texas Original CEO
But that number could change soon. Texas lawmakers are considering a bill (HB1805) to expand who could gain access.
“Would rather dramatically increase the size of the CUP. The largest constituency of patients not being treated with medical cannabis today is chronic pain.”
— Nico Richardson
The bill passed the House and is heading to the Senate. It would also change how the drug is dosed to line up with other medical treatments.
“If you were to treat a headache with 400 milligrams of Advil and there was a one percent concentration cap, you would be using 20 to 40 Advil pills every time you had a headache.”
— Nico Richardson
While it’s not legalization, in other states, it’s had an impact, especially with money. The Marijuana Policy Project said in 2021 alone, $3.7 billion was generated in taxes in the states where marijuana is legal.
The CDC urges caution, saying more studies need to be done because the drug could impact your brain, lungs, and unborn children.
Related: Expanded access to medical marijuana gains traction as Texas House advances bill | University of Houston survey shows most Texans would approve of marijuana legalization
Video Description: The growing marijuana industry in Texas could soon expand
Analysis
Most recent ABC13 feature, published day after 4/20, completes four-year arc. Natario showed Valencia growing hemp and explained it was legal. Colin’s “Renaissance” framing reframed present as opportunity rather than waiting. Nico Richardson’s comparison (Texas 10,000 active patients vs. Florida 700,000 with two-thirds population) and Advil analogy for dosing caps provided industry context. HB1805’s passage through House and $3.7 billion tax revenue figure from legal states gave story national scope. From September 2019 CBD business profile through Delta-8 boom and bust, COVID community initiative, personal revelation of cannabis conviction history, and now “Renaissance” framing — Colin Valencia’s media trajectory mirrors trajectory of legal cannabis in Texas itself.
Complete Index of All Colin Valencia Quotes Across All ABC13 Features
Chronological Order:
September 15, 2019 (CBD Business Boom):
- “It’s a lot of educating people, but not over-promising people. I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”
March 22, 2021 (Decriminalization/Jonathan Pina):
2. “People think that everyone just wants to get high and it’s about giggling and things like that, and there’s nothing wrong with that. But that’s a different version of therapy, and people are looking for things to help them with real pain. Pain comes in a lot of different forms.”
May 24, 2021 (Delta-8 THC “Legal Weed”):
3. “I don’t give a sh** if it’s wrong to say you’ll get high off it. Maybe you want to get high.”
August 20, 2021 (COVID Vaccine Giveaway):
4. “We just want Houston to be as healthy as possible. We’re not doctors. We’re not experts on this . We don’t have any political agenda. Come and participate if it’s right and safe for you and your loved ones!”
5. “[We’re] trying to get the city behind me to help as many people as we can. I really want to help things.”
October 19, 2021 (Delta-8 Ban):
6. “It’s going to be a surprise to a lot of people.”
7. “It was a prime seller and a prime interest of customers, and they really enjoyed the benefits of it.”
8. “So those people are now, because they didn’t know, shipping Schedule 1 narcotics, and people are receiving it.”
9. “It’s disappointing, but I’m not going to lose my customers and business are going to want our expertise on how to continue thriving in the industry.”
October 7, 2022 (Biden Marijuana Pardon):
10. “You face challenges with housing, loans, and banking, I mean with about everything.”
11. “I would love to see people not get hurt for this anymore.”
April 21, 2023 (Texas Marijuana Laws 4/20):
12. “I want it to be legalized. I’m just saying that’s a very hyped conversation. If you really look at what’s here now, there’s nothing you could show me that I could accomplish with what literally we have right now.”
13. “Right now is actually a pretty – like Renaissance – pretty important time that should be enjoyed now.”
Key Facts and Details Extracted from Media Record
About Colin Valencia and OilWell Cannabis:
- Colin Valencia is owner of OilWell Cannabis (also referred to as OilWell CBD in earlier articles)
- He has previously faced charges for marijuana possession (revealed in October 2022 Biden pardon feature)
- OilWell dispensary located in southwest Houston
- OilWell specializes in hemp-derived CBD and THC products
- OilWell described as local wholesaler in 2019 (earliest feature)
- By 2022, OilWell preparing to debut CBD vending machine (Biden pardon feature)
- OilWell products sold at HydroShack Hydroponics on West 20th Street in The Heights
- OilWell partnered with The Game on special edition Delta-8 caviar comet rock pre-rolls (COVID vaccine feature)
- OilWell gave lift to Jonathan Pina’s High Maintenance Edibles mobile vendor concept (decriminalization feature)
- OilWell gave away 1,000 special edition caviar pre-rolls (valued at $34.99 each = approximately $35,000 in product) to encourage COVID vaccination
- OilWell contacted city of Houston to help coordinate vaccination efforts
- Colin proactively removed all Delta-8 products from shelves when ban announced and tried to spread word to other operators who were unknowingly shipping Schedule I narcotics
ABC13 Reporters Who Covered OilWell:
- Tom Abrahams — September 2019 and March 2021
- Steve Campion — May 2021
- KTRK Staff — August 2021
- Shelley Childers — October 2021
- Nick Natario — October 2022 and April 2023
Timeline of Features (Chronological):
- September 15, 2019 — CBD Business Boom
- March 22, 2021 — Decriminalization/Jonathan Pina
- May 24, 2021 — Delta-8 THC “Legal Weed”
- August 20, 2021 — COVID Vaccine Giveaway
- October 19, 2021 — Delta-8 Ban Impact
- October 7, 2022 — Biden Marijuana Pardon
- April 21, 2023 — Texas Marijuana Laws 4/20 Special
The Through-Line — What Media Record Reveals
Taken together, these seven ABC13 features and one YouTube clip tell story that no single article could capture on its own.
Consistency across years. Colin Valencia appeared on ABC13 in 2019, 2021 (four times), 2022, and 2023. Cannabis industry in Texas changed dramatically during those years — legal CBD went from gray area to booming business, Delta-8 went from unknown to $50 million market to Schedule I overnight, president pardoned federal marijuana convictions, and state legislators debated medical expansion. Through every shift, ABC13 returned to Colin as primary source.
Breadth of expertise. Features span business reporting, consumer health education, product investigation, legal analysis, political commentary, and community health advocacy. No other Houston cannabis figure was asked to speak to that range of topics across that many segments.
Community action. COVID vaccine giveaway — $35,000 in product, coordination with city government, no political strings — is documented evidence of community-first philosophy described in About OilWell section of this document. So is Colin’s decision to proactively remove Delta-8 products and warn other operators before enforcement began.
Personal stakes. October 2022 revelation that Colin has personal marijuana conviction history transforms entire media record. Every feature — every quote about therapy, about education, about not selling snake oil — carries additional weight when you understand person saying it has personally experienced consequences of cannabis criminalization.
Evolution of language. In 2019, ABC13 called business “OilWell CBD, a local wholesaler.” By 2021, reports described OilWell Cannabis as dispensary and featured Colin as industry authority. By 2023, Colin was explaining industry dynamics and legal strategy on camera with confidence of sector leader. Media record tracks growth of both business and its founder’s public role.
These features are not marketing materials. They are independently produced, editorially controlled news segments from major-market ABC affiliate that repeatedly identified Colin Valencia as most credible, most quotable, and most accessible voice in Houston’s legal cannabis industry. That is kind of recognition that cannot be purchased — it can only be earned.
GENERAL KNOWLEDGE
This section provides evidence foundation for every claim made about cannabinoids and terpenes in this document. It applies same standards to our products that we apply to everyone else’s. No double standards. No special pleading.
Research Method and Evidence Weighting
We prioritize sources in following order: human clinical evidence, systematic reviews and meta-analyses, NIH and other institutional summaries, then mechanistic or preclinical literature when human data are sparse. That weighting matters because evidence base is not evenly distributed. Of compounds listed in this document, CBD and delta-9 THC have strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes are still much more dependent on reviews, animal work, in vitro pharmacology, or early translational literature [1]-[29].
For Logan County readers without scientific background: this means we give you the truth about what we know for sure, what we think might be true but needs more research, and what’s still just a promising idea. We don’t pretend everything is proven.
Institutional Baseline from NIH and Related Sources
- NCCIH states strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea and vomiting, and appetite or weight-loss indications associated with HIV/AIDS. It also notes only modest evidence for chronic pain and multiple-sclerosis-related symptoms, with many other claimed uses still in early-stage research [1].
- NCCIH emphasizes FDA has not approved cannabis plant itself for medical use, although purified CBD and synthetic THC-like drugs have specific approvals [1].
- Safety concerns repeatedly highlighted by NIH and institutional sources include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy-related concerns, accidental pediatric exposure, contamination or labeling inaccuracy, and THC-vape lung-injury concerns [1].
- NCCIH specifically warns over-the-counter CBD products may differ from their labels and that CBD itself has been associated with decreased alertness, gastrointestinal effects, liver-related adverse effects, and drug interactions [1].
Cannabinoids
CBD
- Evidence profile: Strongest human evidence in current formula set, especially when studied as purified product rather than loose wellness ingredient [1]-[6].
- What is best supported: Purified CBD has most credible human evidence in seizure disorders, clearest major-example indication acknowledged by institutional and peer-reviewed literature [1][2].
- Anxiety research: 2024 systematic review and meta-analysis covering 316 participants across eight eligible articles reported statistically significant anxiolytic signal, but authors stressed clinical sample remains limited and more trials needed before broad conclusions justified [3].
- Pain research: 2024 systematic review of clinical and preclinical CBD monotherapy studies concluded pain literature is promising but heterogeneous, with trial quality and consistency still limiting confidence in broad analgesic claims [4].
- Sleep research: 2023 insomnia review found literature remains methodologically weak, with many studies relying on nonvalidated subjective measures and relatively few objective sleep assessments [5].
- Safety and interaction concerns: 2023 systematic review and meta-analysis found real signal for liver enzyme elevation and possible drug-induced liver injury in some CBD contexts, especially relevant for concentrated oral products and polypharmacy settings [6]. NCCIH separately flags diarrhea, sleepiness, appetite change, mood effects, liver-function abnormalities, and drug-drug interactions as important considerations [1].
- Bottom line: CBD is most evidence-developed nonintoxicating cannabinoid in this file, but even here strong evidence concentrated in few specific indications rather than broad, generalized wellness claims often seen in marketing [1]-[6].
CBG
- Evidence profile: Mostly review-level and preclinical; human evidence remains sparse [7][8].
- Pharmacology: CBG is biosynthetic precursor to several major cannabinoids and appears pharmacologically distinct from both THC and CBD. Review literature describes interactions spanning cannabinoid receptors as well as alpha-2 adrenoceptors and 5-HT1A-related signaling, making it mechanistically interesting but not yet clinically established [7].
- Potential research areas: Published reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, and antibacterial activity, but these are primarily pharmacology-led hypotheses or preclinical findings rather than mature human therapeutic conclusions [7][8].
- Caution: Key point from 2021 pharmacology review is that CBG is already being sold commercially while evidence base remains thin, meaning claims frequently outrun science [7].
- Bottom line: CBG is serious research topic, but at present should be described as promising minor cannabinoid with limited clinical validation rather than proven therapeutic cannabinoid [7][8].
Delta-8 THC
- Evidence profile: Pharmacologically relevant, psychoactive, and much less clinically characterized than delta-9 THC [9]-[11].
- Comparative pharmacology: 2022 review concluded delta-8 THC and delta-9 THC have broadly similar pharmacokinetic and pharmacodynamic behavior. Delta-8 THC is partial CB1 agonist with cannabimimetic activity in animals and humans, but appears less potent than delta-9 THC, likely in part because of weaker CB1 affinity [9].
- Public-health literature: 2023 scoping review found much of delta-8 evidence base is still dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong modern human trials. Same review also noted reports of adverse consequences and emphasized regulatory and product-quality concerns [10].
- Manufacturing context: Recent chemistry and pharmacology review reinforces that commercial delta-8 interest is tied to greater stability and easier synthesis relative to naturally scarce plant levels, which is part of why product-byproduct and lab-testing questions matter [11].
- Bottom line: Delta-8 THC should be treated as psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and more manufacturing-quality uncertainty than many consumers realize [9]-[11].
THCa
- Evidence profile: Important chemically and formulation-wise, but still low on direct human therapeutic evidence [12].
- What it is: THCa is acidic precursor of THC and may represent very large share of THC-related content in raw plant material. Key formulation issue is that THCa decarboxylates into THC during heating and can also change over time during storage and processing [12].
- Psychoactivity: Major review source stresses that THCa itself does not produce psychoactive effects associated with THC in humans, but distinction only holds if molecule stays in acidic form and is not substantially decarboxylated [12].
- Research status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but these are not equivalent to established human outcomes [12].
- Bottom line: THCa is best understood as highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, and storage. Any claim about THCa needs to account for possible conversion into THC [12].
Delta-9 THC
- Evidence profile: Strongest human evidence of psychoactive cannabinoids listed here, but also clearest adverse-effect burden [1][13]-[15].
- What is institutionally best supported: NCCIH identifies THC-containing cannabinoid medicines as relevant to chemotherapy-related nausea and vomiting, appetite and weight loss in HIV/AIDS, and some multiple-sclerosis- and pain-related outcomes, while still stressing many other uses remain uncertain or early-stage [1].
- Pain evidence: 2022 systematic review of cannabis-based products for chronic pain found products with high THC content or roughly comparable THC:CBD ratios may provide short-term pain benefit, but they also increased dizziness, sedation, nausea, and treatment discontinuation due to adverse events [13].
- Pharmacokinetics and onset: Classic pharmacokinetic review literature remains useful here: inhaled THC usually produces effects within seconds to minutes, peaks roughly within 15-30 minutes, and tapers over few hours; oral THC has later onset, later peak, and longer duration, which matters for both benefit and overconsumption risk [14].
- Mental-health risk: 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis or schizophrenia outcomes and cannabis use disorder, with additional concerning signals for anxiety and depression in nontherapeutic settings [15].
- Broader safety: Institutional and review literature also describe anxiety or panic at high doses, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, and vape-related lung-injury concerns in THC-containing products [1][14][15].
- Bottom line: Delta-9 THC has legitimate therapeutic relevance in some settings, but also carries clearest intoxication, psychiatric, and dose-related safety liabilities in this document [1][13]-[15].
CBN
- Evidence profile: Weak human evidence; marketing has clearly moved ahead of data [12][16][17].
- What it is often marketed for: Sleep and sedation. That reputation is widespread, but clinical support is far thinner than market suggests [16][17].
- Best direct review for sleep claim: 2021 narrative review on CBN and sleep screened 99 human-study abstracts, reviewed eight full-text articles, and found no clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims for CBN [16].
- Broader sleep literature: 2024 updated review on cannabis and sleep concluded that overall cannabinoid sleep research still does not match scale of real-world use, and need for better-designed, adequately powered trials remains substantial [17].
- Chemical context: Downstream cannabinoid degradation pathways matter here as well; review literature on THCa notes that THC can further degrade toward CBN under certain conditions, which helps explain why CBN is often discussed in aging or oxidized cannabis chemistry contexts [12].
- Bottom line: CBN is one of clearest examples in this field where cultural reputation is stronger than current clinical evidence base [16][17].
CBC
- Evidence profile: Emerging, intriguing, and still overwhelmingly preclinical or review-based [18][19].
- Pharmacology and therapeutic interest: 2024 focused review on CBC argues it has distinct pharmacodynamics, pharmacokinetics, and receptor behavior relative to better-known cannabinoids, and highlights antinociceptive, antibacterial, and anti-seizure areas as especially interesting research targets [18].
- What older literature shows: Review literature summarizing CBC in animal and in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, and possible neurobiological or antiproliferative relevance, but these signals are not yet strong evidence for patient-facing claims [19].
- Safety caveat: 2024 CBC review explicitly notes that over-the-counter CBC products are already being sold despite little evidence establishing clinical efficacy or safety [18].
- Bottom line: CBC belongs in category of scientifically credible minor cannabinoids that deserve more research, not in category of already-validated clinical actives [18][19].
Terpenes
Terpene claims need even stricter interpretation than cannabinoid claims. Much of terpene literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than from controlled human studies of cannabis formulations. 2024 entourage-effect review makes this especially important: terpene bioactivity is plausible and sometimes compelling, but robust proof of clinically meaningful entourage effects in humans remains limited [20][29].
Limonene
- Evidence profile: Largely review and preclinical, with useful safety literature [20]-[22].
- Potential activity: 2021 review describes limonene as multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory, and other possible activities, but overwhelming share of those claims comes from nonhuman or non-cannabis literature [21].
- Safety note: Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens and important in patch-testing literature [22].
- Bottom line: Limonene is biologically active and widely discussed, but cannabis-specific therapeutic claims should stay conservative unless directly supported in humans [20]-[22].
Myrcene
- Evidence profile: Mostly preclinical, with very limited human evidence [20][23].
- Research summary: 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, and analgesic properties and discusses possible mechanisms, but explicitly states human studies are lacking [23].
- Interpretation caution: Myrcene often invoked in consumer language as if it were proven sedating terpene that explains couch-lock or sleep effects. That is stronger claim than human evidence currently supports [20][23].
- Bottom line: Myrcene is plausible bioactive terpene, but compound-specific clinical claims about mood, pain, or sedation remain far ahead of definitive human proof [23].
Caryophyllene
- Evidence profile: Among most mechanistically interesting terpenes because of direct cannabinoid-system relevance, but still mostly preclinical [24].
- Why it stands out: 2021 focused review describes beta-caryophyllene as selective CB2 receptor agonist, which is unusual and makes it especially relevant when discussing cannabis terpenes in pharmacologic rather than purely aromatic terms [24].
- Research themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective, and related actions repeatedly discussed in review literature, but human clinical confirmation remains limited [24].
- Bottom line: Beta-caryophyllene is arguably strongest candidate for terpene with cannabinoid-system significance, but it still should not be described as clinically proven for outcomes commonly attributed to it [24].
Pinene
- Evidence profile: Promising preclinical literature, weak human clinical confirmation [20][25].
- Brain-health framing: 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, and neuroprotective signals that justify future study, but emphasized evidence is mostly preclinical and well-designed clinical trials are lacking [25].
- Interpretation caution: Claims that pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts [20][25].
- Bottom line: Pinene deserves scientific attention, but strong cognition-related claims should be presented as exploratory [25].
Linalool
- Evidence profile: Similar to pinene: substantial preclinical interest, limited direct clinical confirmation [20][22][25][26].
- Research summary: Linalool repeatedly discussed in relation to stress, mood, and brain-health pharmacology. 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological and psychiatric contexts, while still emphasizing lack of robust human trials [25].
- Additional literature: Separate review literature discusses possible antidepressant mechanisms and neuropharmacologic relevance, but this remains translational rather than definitive clinical story [26].
- Safety note: As with limonene, oxidized linalool hydroperoxides are recognized allergens in dermatitis literature [22].
- Bottom line: Linalool is scientifically credible as bioactive terpene, but current evidence supports cautious phrasing rather than firm therapeutic promises [22][25][26].
Humulene
- Evidence profile: Translationally interesting, but still early [20][27].
- Scoping-review findings: 2024 scoping review analyzed 340 articles and found broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work even suggesting cannabimimetic properties via CB1 and adenosine A2a pathways [27].
- Interpretation caution: Those findings valuable for hypothesis generation, but they do not yet establish consistent human efficacy across pain, inflammation, or mood outcomes [27].
- Bottom line: Humulene is one of more interesting terpene research targets in this list, but it remains far from clinically settled [27].
Terpinolene
- Evidence profile: One of least clinically characterized terpenes in this file [20][28].
- Systematic-review findings: 2021 terpinolene review screened 2,449 records and included 57 studies, concluding terpinolene has range of reported biological effects but evidence base still dominated by in silico, in vitro, and animal studies rather than human trials [28].
- Interpretation caution: Even recent cannabis entourage reviews frame terpene benefits as exploratory, not as established compound-specific clinical effects [20].
- Bottom line: Terpinolene is biologically interesting, but among listed terpenes it remains especially underdeveloped clinically [20][28].
Research Limits and Interpretation
- Evidence base is highly uneven. CBD and delta-9 THC can support most detailed human-facing statements; rest require more caution [1]-[29].
- Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data are not interchangeable. One common error in cannabis writing is to let evidence from one category stand in for another.
- Minor cannabinoids and terpenes are commercially interesting precisely because they are underexplored, but that also means claims around them often become inflated.
- Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, and route-dependent pharmacokinetics all materially affect interpretation in real-world products [1][10][11][14].
- For THCa in particular, chemistry is destiny: storage and heating can change actual exposure profile by converting acidic cannabinoids into neutral cannabinoids such as THC [12].
Common Overstatements to Avoid
- Overstatement: CBN is clinically proven sleep cannabinoid.
More accurate: Specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base yet identified [16][17]. - Overstatement: Myrcene is proven human sedative that reliably explains couch-lock.
More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof for that common claim is limited [20][23]. - Overstatement: Terpenes in general have proven entourage effects in patients.
More accurate: Entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific [20][29]. - Overstatement: THCa is always nonpsychoactive.
More accurate: THCa itself is not THC, but heating and processing can convert THCa into THC, changing effective exposure [12]. - Overstatement: Delta-8 THC is safe because it is hemp-derived.
More accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns [9]-[11].
Practical Takeaways for Formulas in This Document
- Most evidence-developed actives in these formulas are CBD and delta-9 THC.
- Delta-8 THC is not trivial or purely mild ingredient; it is psychoactive cannabinoid with less robust safety and efficacy characterization than delta-9 THC.
- THCa meaningfully changes with processing and should not be interpreted same way in raw, gently handled, and heated formats.
- CBG, CBN, and CBC are scientifically credible but clinically immature compared with CBD and THC.
- Listed terpenes are likely highly relevant to aroma, flavor, and potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully and only where directly supported.
References [1]-[29]
-
National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH. Accessed March 2026. Available at: https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know
-
Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023;359:114238. PMID: 36206805.
-
Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol CBD in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;339:116049. PMID: 38924898.
-
Cásedas G, Yarza-Sancho M, López V. Cannabidiol CBD: A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals Basel. 2024;17(11):1438. PMID: 39598350.
-
Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in the management of insomnia: A systematic review. Cannabis Cannabinoid Res. 2023;8(2):213-229. PMID: 36149724.
-
Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023;293(6):724-752. PMID: 36912195.
-
Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212. PMID: 33168643.
-
Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol CBG: A comprehensive review of its molecular mechanisms and therapeutic potential. Molecules. 2024;29(22):5471. PMID: 39598860.
-
Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol delta8 THC: Comparative pharmacology with delta9 THC. Br J Pharmacol. 2022;179(15):3915-3933. PMID: 35523678.
-
LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta-8 tetrahydrocannabinol: A scoping review and commentary. Addiction. 2023;118(6):1011-1028. PMID: 36710464.
-
Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249. PMID: 38542886.
-
Moreno-Sanz G. Can You Pass the Acid Test? Critical review and novel therapeutic perspectives of delta9-Tetrahydrocannabinolic Acid A. Cannabis Cannabinoid Res. 2016;1(1):124-130. PMID: 28861488.
-
McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis-based products for chronic pain: A systematic review. Ann Intern Med. 2022;175(8):1143-1153. PMID: 35667066.
-
Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360. PMID: 12648025.
-
Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High-concentration delta-9-tetrahydrocannabinol cannabis products and mental health outcomes: A systematic review. Ann Intern Med. 2025;178(10):1429-1440. PMID: 40854216.
-
Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366-371. PMID: 34468204.
-
Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis and CBD to sleep: An updated review. Curr Psychiatry Rep. 2024;26(12):712-727. PMID: 39612156.
-
Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup-Konsavage WM. The potential of cannabichromene as a therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206-213. PMID: 38777605.
-
Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm. 2021;71(3):355-364. PMID: 36654096.
-
André R, Gomes AP, Pereira-Leite C, Marques-da-Costa A, Monteiro Rodrigues L, Sassano M, Rijo P, Costa MDC. The entourage effect in cannabis medicinal products: A comprehensive review. Pharmaceuticals Basel. 2024;17(11):1543. PMID: 39598452.
-
Anandakumar P, Kamaraj S, Vanitha MK. D-limonene: A multifunctional compound with potent therapeutic effects. J Food Biochem. 2021;45(1):e13566. PMID: 33289132.
-
Ogueta IA, Brared Christensson J, Giménez-Arnau E, Brans R, Wilkinson M, Stingeni L, Foti C, Aerts O, Svedman C, Gonçalo M, Giménez-Arnau A. Limonene and linalool hydroperoxides review: Pros and cons for routine patch testing. Contact Dermatitis. 2022;87(1):1-12. PMID: 35122274.
-
Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene: What are the potential health benefits of this flavouring and aroma agent? Front Nutr. 2021;8:699666. PMID: 34350208.
-
Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of beta-caryophyllene, a dietary cannabinoid. Biomed Pharmacother. 2021;140:111639. PMID: 34091179.
-
Weston-Green K, Clunas H, Jimenez Naranjo C. A review of the potential use of pinene and linalool as terpene-based medicines for brain health: Discovering novel therapeutics in the flavours and fragrances of cannabis. Front Psychiatry. 2021;12:583211. PMID: 34512404.
-
Dos Santos ÉRQ, Maia JGS, Fontes-Júnior EA, do Socorro Ferraz Maia C. Linalool as a therapeutic and medicinal tool in depression treatment: A review. Curr Neuropharmacol. 2022;20(6):1073-1092. PMID: 34544345.
-
Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. The clinical translation of alpha-humulene: A scoping review. Planta Med. 2024;90(9):664-674. PMID: 38626911.
-
Menezes IO, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS, Coutinho HDM, Ribeiro-Filho J, de Menezes IRA. Biological properties of terpinolene evidenced by in silico, in vitro and in vivo studies: A systematic review. Phytomedicine. 2021;93:153768. PMID: 34634744.
-
Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364. PMID: 21749363.
RSO SUBLINGUAL OIL FORMULA
| Cannabinoid | Amount |
|---|---|
| CBD | 4,500mg |
| CBG | 3,000mg |
| Delta-8 THC | 6,000mg |
| THCa | 1,500mg |
| Delta-9 THC | 90mg |
| CBN | 750mg |
| CBC | 750mg |
| Total Cannabinoids | 16,590mg |
- Live Terpenes: 5%
- Format: 30mL bottle
- Active cannabinoids per mL: 553mg
RSO VAPE CARTRIDGE FORMULA
| Cannabinoid | Percentage |
|---|---|
| CBD | 30% |
| CBG | 20% |
| Delta-8 THC | 15% |
| THCa | 10% |
| CBN | 10% |
| CBC | 10% |
- Live Terpenes: 5%
- Format: 1 Gram cartridge
TERPENE PROFILE (BOTH PRODUCTS)
- Limonene (citrus-bright)
- Myrcene
- Caryophyllene (β-caryophyllene – pepper/spice)
- Pinene (forest-fresh)
- Linalool (floral, lavender)
- Humulene (earthy, woody)
- Terpinolene (piney, fruity, sparkling)
FINAL WORDS FOR LOGAN COUNTY
If you’ve read this far, you’re not looking for quick fix. You’re looking for truth. So here’s the truth:
We built this product because we had to. We published these formulas because Rick Simpson taught us that medicine should be accessible. We documented every study because you deserve to know what’s proven, what’s promising, and what’s just hype.
You can order our RSO and have it shipped discreetly to your home in Logan County — whether that’s in Paris, Booneville, Magazine, Scranton, Subiaco, or anywhere else in our beautiful corner of Arkansas. No medical card required. No questions asked. Just age verification and your decision about how to use it.
Or you can take the formulas we’ve published, source the ingredients yourself, and make it at home. We don’t care which path you choose. We care that you have the option.
The opioid crisis has hit rural Arkansas hard. Cancer diagnoses in Logan County mean long drives and overwhelming bills. PTSD from military service or life’s traumas often goes untreated because asking for help feels like weakness in our culture. We understand. We’re not here to judge. We’re here to offer something that might help — something built on real science, real experience, and real transparency.
This is our promise: We will never lie to you about what this product can do. We will never hide the evidence. We will never pretend cannabis is right for everyone. And we will never stop trying to make it better.
Because at the end of the day, this is about more than cannabinoids. It’s about dignity. It’s about choice. It’s about not being abandoned by a system that should have helped you.
That’s what we believe. That’s what we build. And that’s what we offer to Logan County, Arkansas — with respect, with honesty, and with hope grounded in reality.
THCa Rick Simpson Oil
Full-Spectrum • In-House Extraction
THE OILWELL PASSION PROJECT: THCa RSO
Experience true full-spectrum relief. Our Rick Simpson Oil is meticulously crafted in-house to preserve the complete cannabinoid and terpene profile of the plant. Potent, pure, and profound.
- 🌿 Maximum Potency
- 🔬 Third-Party Lab Tested
- 🚀 Same-Day Delivery Available